# Region-Specific NRF2 Signaling in HIV-Associated Neurocognitive Disorders: A Transcriptomic and Computational Histology Study

**Authors:** Grazia Scuderi, Serena Spampinato, Michelino Di Rosa, Paolo Fagone, Giuseppe Nunnari

PMC · DOI: 10.3390/genes17020195 · Genes · 2026-02-05

## TL;DR

This study explores how the NRF2 antioxidant pathway functions in different brain regions during HIV-related cognitive disorders, finding it is selectively activated in white matter during severe cases.

## Contribution

The study reveals region-specific NRF2 signaling activation in HIV encephalitis, offering insights into targeted therapeutic strategies.

## Key findings

- Low-to-medium baseline expression of NRF2-related genes was observed in the normal cortex.
- White matter showed robust NRF2 transcriptional activation specifically in HIV encephalitis.
- NRF2 signaling remains coordinated across brain regions in HAND, with selective activation in white matter.

## Abstract

Background/Objectives. Oxidative stress is a key contributor to HIV-associated neurocognitive disorders (HANDs), yet the regional organization and functional engagement of the NRF2 antioxidant pathway in the human brain remain incompletely defined. This study aimed to characterize NRF2 pathway architecture, baseline brain expression, and disease-associated transcriptional and coexpression remodeling across HAND stages. Methods. The NRF2 signaling network was reconstructed using curated pathway data and protein–protein interaction analysis to identify central hub genes. Baseline expression in the normal human cortex was assessed using the Human Protein Atlas. Transcriptomic profiling of postmortem brain samples from individuals with HAND (GSE35864) was performed using differential expression, hierarchical clustering, and region-specific coexpression analyses across white matter, frontal cortex, and basal ganglia. Results. Low-to-medium baseline expression of NRF2-related genes was observed in the normal cortex. Bulk differential expression revealed minimal NRF2 pathway modulation in the frontal cortex and basal ganglia. On the other hand, white matter exhibited robust NRF2 transcriptional activation specifically in HIV encephalitis (HIVE). Coexpression analysis performed specifically within HAND samples revealed a highly coordinated transcriptional organization of the NRF2 signaling network across all analyzed brain regions. Conclusions. NRF2 signaling in HAND is preserved as a coordinated transcriptional network but is selectively activated in white matter during encephalitic disease, highlighting region- and cell-type-targeted therapeutic opportunities.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551]
- **Diseases:** HIV encephalitis (MONDO:0020689)

## Full-text entities

- **Genes:** EPHA2 (EPH receptor A2) [NCBI Gene 1969] {aka ARCC2, CTPA, CTPP1, CTRCT6, ECK}, PRDX1 (peroxiredoxin 1) [NCBI Gene 5052] {aka MSP23, NKEF-A, NKEFA, PAG, PAGA, PAGB}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, GCLC (glutamate-cysteine ligase catalytic subunit) [NCBI Gene 2729] {aka CNSHA7, GCL, GCS, GLCL, GLCLC}, OGG1 (8-oxoguanine DNA glycosylase) [NCBI Gene 4968] {aka HMMH, HOGG1, MUTM, OGH1}, ABCC5 (ATP binding cassette subfamily C member 5) [NCBI Gene 10057] {aka ABC33, EST277145, MOAT-C, MOATC, MRP5, SMRP}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, MGST3 (microsomal glutathione S-transferase 3) [NCBI Gene 4259] {aka GST-3, GST-III}, SLC39A12 (solute carrier family 39 member 12) [NCBI Gene 221074] {aka LZT-Hs8, ZIP-12, ZIP12, bA570F3.1}, CYP2A6 (cytochrome P450 family 2 subfamily A member 6) [NCBI Gene 1548] {aka CPA6, CYP2A, CYP2A3, CYPIIA6, P450C2A, P450PB}, BLVRB (biliverdin reductase B) [NCBI Gene 645] {aka BVRB, FLR, HEL-S-10, SDR43U1}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}, NQO1 (NAD(P)H quinone dehydrogenase 1) [NCBI Gene 1728] {aka DHQU, DIA4, DTD, NMOR1, NMORI, QR1}, vpr (Vpr) [NCBI Gene 155807], NRG1 (neuregulin 1) [NCBI Gene 3084] {aka ARIA, GGF, GGF2, HGL, HRG, HRG1}, GCLM (glutamate-cysteine ligase modifier subunit) [NCBI Gene 2730] {aka GLCLR}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CES3 (carboxylesterase 3) [NCBI Gene 23491] {aka ES31}, HBEGF (heparin binding EGF like growth factor) [NCBI Gene 1839] {aka DTR, DTS, DTSF, HEGFL}, ABCC2 (ATP binding cassette subfamily C member 2) [NCBI Gene 1244] {aka ABC30, CMOAT, DJS, MRP2, cMRP}, Nef [NCBI Gene 156110], SMOX (spermine oxidase) [NCBI Gene 54498] {aka C20orf16, PAO, PAO-1, PAO1, PAOH, PAOH1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, GPX2 (glutathione peroxidase 2) [NCBI Gene 2877] {aka GI-GPx, GPRP, GPRP-2, GPx-2, GPx-GI, GSHPX-GI}, TXNRD1 (thioredoxin reductase 1) [NCBI Gene 7296] {aka GRIM-12, TR, TR1, TRXR1, TXNR, TXNR1}, CBR3 (carbonyl reductase 3) [NCBI Gene 874] {aka HEL-S-25, SDR21C2, hCBR3}, SRXN1 (sulfiredoxin 1) [NCBI Gene 140809] {aka C20orf139, Npn3, SRX, SRX1}, CES2 (carboxylesterase 2) [NCBI Gene 8824] {aka CE-2, CES2A1, PCE-2, iCE}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, GSTM1 (glutathione S-transferase mu 1) [NCBI Gene 2944] {aka GST1, GSTM1-1, GSTM1a-1a, GSTM1b-1b, GTH4, GTM1}, GSTK1 (glutathione S-transferase kappa 1) [NCBI Gene 373156] {aka GST, GST 13-13, GST13, GST13-13, GSTK1-1, hGSTK1}, RXRA (retinoid X receptor alpha) [NCBI Gene 6256] {aka NR2B1, RXR-alpha, RXRalpha}, ADH7 (alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide) [NCBI Gene 131], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, ABCC3 (ATP binding cassette subfamily C member 3) [NCBI Gene 8714] {aka ABC31, EST90757, MLP2, MOAT-D, MRP3, cMOAT2}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950] {aka DFN7, FAEES3, GST3, GSTP, GSTP1-1, HEL-S-22}, TXN (thioredoxin) [NCBI Gene 7295] {aka TRDX, TRX, TRX1, TXN1, Trx80}, MAFG (MAF bZIP transcription factor G) [NCBI Gene 4097] {aka hMAF}, MGST2 (microsomal glutathione S-transferase 2) [NCBI Gene 4258] {aka GST2, MGST-II}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, TAT (tyrosine aminotransferase) [NCBI Gene 6898], GPX3 (glutathione peroxidase 3) [NCBI Gene 2878] {aka GPx-P, GSHPx-3, GSHPx-P}, ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) [NCBI Gene 3700] {aka GP120, H4P, IHRP, ITI-HC4, ITIHL1, PK-120}, ALDH3A1 (aldehyde dehydrogenase 3 family member A1) [NCBI Gene 218] {aka ALDH3, ALDHIII}, GSTM4 (glutathione S-transferase mu 4) [NCBI Gene 2948] {aka GSTM4-4, GTM4}, GSTA1 (glutathione S-transferase alpha 1) [NCBI Gene 2938] {aka GST-epsilon, GST2, GSTA1-1, GTH1}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}
- **Diseases:** neurological disease (MESH:D020271), oligodendrocyte dysfunction (MESH:D056784), AIDS (MESH:D000163), stroke (MESH:D020521), encephalitic (MESH:D010301), HANDs (MESH:D016263), HAND (MESH:C574275), calcium overload (MESH:D019190), chronic inflammation (MESH:D007249), neurodegeneration (MESH:D019636), injury to (MESH:D014947), mitochondrial damage (MESH:D028361), Parkinson's disease (MESH:D010300), neurotoxic (MESH:D020258), Alzheimer's disease (MESH:D000544), neuroinflammation (MESH:D000090862), neurological complications (MESH:D002493), neuronal damage (MESH:D009410), multiple sclerosis (MESH:D009103), HIV (MESH:D015658), neurological deterioration (MESH:D009422), cognitive decline (MESH:D003072), infection (MESH:D007239), HIV encephalitis (MESH:D004660), Neurocognitive Disorders (MESH:D019965)
- **Chemicals:** iron (MESH:D007501), ceramide (MESH:D002518), 8-oxo-2'-deoxyguanosine (MESH:D000080242), sulforaphane (MESH:C016766), glutathione (MESH:D005978), DMF (MESH:D000069462), polyphenols (MESH:D059808), lipid (MESH:D008055), N-acetylcysteine (MESH:D000111), ROS (MESH:D017382), potassium (MESH:D011188), heme (MESH:D006418), peroxide (MESH:D010545), bardoxolone methyl (MESH:C445068)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941223/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941223/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941223/full.md

---
Source: https://tomesphere.com/paper/PMC12941223